123 related articles for article (PubMed ID: 11459209)
21. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
22. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Zhao L; Kestell P; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
[TBL] [Abstract][Full Text] [Related]
23. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
Miners JO; Valente L; Lillywhite KJ; Mackenzie PI; Burchell B; Baguley BC; Kestell P
Cancer Res; 1997 Jan; 57(2):284-9. PubMed ID: 9000569
[TBL] [Abstract][Full Text] [Related]
24. High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zho S; Chiang D; Chin R; Kestell P; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb; 767(1):19-26. PubMed ID: 11863291
[TBL] [Abstract][Full Text] [Related]
25. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Kestell P; Baguley BC; Paxton JW
Biochem Pharmacol; 2003 Jan; 65(1):109-20. PubMed ID: 12473385
[TBL] [Abstract][Full Text] [Related]
26. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Paxton JW; Tingle MD; Kestell P
Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
[TBL] [Abstract][Full Text] [Related]
27. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
Jameson MB; Baguley BC; Kestell P; Zhao L; Paxton JW; Thompson PI; Waller S;
Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
[TBL] [Abstract][Full Text] [Related]
29. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
31. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Chung F; Palmer BD; Muller GW; Man HW; Kestell P; Baguley BC; Ching LM
Oncol Res; 2003; 14(2):75-82. PubMed ID: 14649541
[TBL] [Abstract][Full Text] [Related]
32. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
Wang LC; Ching LM; Paxton JW; Kestell P; Sutherland R; Zhuang L; Baguley BC
Invest New Drugs; 2009 Jun; 27(3):280-4. PubMed ID: 18696010
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
35. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
Zhao L; Ching LM; Kestell P; Baguley BC
Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
Pruijn FB; van Daalen M; Holford NH; Wilson WR
Cancer Chemother Pharmacol; 1997; 39(6):541-6. PubMed ID: 9118467
[TBL] [Abstract][Full Text] [Related]
37. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
Pang JH; Cao Z; Joseph WR; Baguley BC; Ching LM
Eur J Cancer; 1998 Jul; 34(8):1282-9. PubMed ID: 9849492
[TBL] [Abstract][Full Text] [Related]
38. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiat Res; 2001 Nov; 156(5 Pt 1):503-9. PubMed ID: 11604063
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
[TBL] [Abstract][Full Text] [Related]
40. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
Galbraith SM; Rustin GJ; Lodge MA; Taylor NJ; Stirling JJ; Jameson M; Thompson P; Hough D; Gumbrell L; Padhani AR
J Clin Oncol; 2002 Sep; 20(18):3826-40. PubMed ID: 12228202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]